文献速递眼底病与葡萄膜炎

雷珠单抗治疗糖尿病黄斑水肿时糖尿病视网膜病变严重程度的变化:DRCR.net Protocol I 5年报告

CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report.
PubMed 文献 · Retina · 2018-01-01

本研究基于DRCR.net Protocol I,评估接受雷珠单抗治疗的糖尿病黄斑水肿眼在5年间糖尿病视网膜病变(DR)严重程度的变化。基线非增殖性DR眼在1、3、5年分别有29%、28%、32%改善,增殖性DR眼分别为38%、35%、23%;5年累计恶化概率非增殖性DR为18%(95%CI:14%-25%),增殖性DR为31%(95%CI:23%-42%)(P=0.01)。结论认为雷珠单抗治疗糖尿病黄斑水肿期间DR严重程度可有有利变化,并伴随抗VEGF治疗逐年减少。

要点

  • 非增殖性DR眼5年累计恶化概率为18%,增殖性DR眼为31%,差异有统计学意义(P=0.01)。
  • 非增殖性DR眼1、3、5年DR改善比例分别为29%、28%、32%;增殖性DR眼分别为38%、35%、23%。
  • 雷珠单抗注射次数在1、3、5年逐年减少,非增殖性DR眼均值分别为8.1、2.2、1.8次,增殖性DR眼分别为9.0、2.3、1.7次。

核心结论

  • 接受雷珠单抗治疗糖尿病黄斑水肿的个体在5年期间DR严重程度可有有利变化,并伴随抗VEGF治疗逐年减少。

研究设计与样本

  • 基于DRCR.net Protocol I研究,评估接受雷珠单抗治疗的糖尿病黄斑水肿眼在5年间DR严重程度变化。
  • DR严重程度通过研究访视和年度眼底照片评估,估计年度检查时改善比例及5年累计恶化概率。
  • 基线非增殖性DR参与者235例,增殖性DR参与者111例。

主要发现

  • 基线非增殖性DR眼在1、3、5年DR改善比例分别为29%、28%、32%。
  • 基线增殖性DR眼在1、3、5年DR改善比例分别为38%、35%、23%。
  • 5年累计恶化概率非增殖性DR眼为18%(95%CI:14%-25%),增殖性DR眼为31%(95%CI:23%-42%)(P=0.01)。
  • 第1、3、5年雷珠单抗平均注射次数(SD)非增殖性DR眼分别为8.1(2.5)、2.2(2.6)、1.8(2.6)次,增殖性DR眼分别为9.0(2.8)、2.3(2.9)、1.7(2.6)次。
  • 改善比例或恶化率未随时间变化。

临床怎么用

  • 对糖尿病黄斑水肿患者采用雷珠单抗治疗时,应关注DR严重程度的长期变化,并按随访计划评估眼底情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore 5-year changes from baseline in diabetic retinopathy severity among eyes treated with ranibizumab for diabetic macular edema. METHODS: Diabetic retinopathy severity was assessed from study visits and annual fundus photographs among participants in Protocol I (DRCR.net). The proportion of eyes that improved at annual examinations and the cumulative probability of worsening through 5 years were estimated. RESULTS: Among 235 participants with nonproliferative diabetic retinopathy at baseline, there were 29%, 28%, and 32% of eyes with retinopathy improvement at 1, 3, and 5 years, respectively. Among 111 participants with proliferative diabetic retinopathy, corresponding improvement percentages were 38%, 35%, and 23%. The 5-year cumulative probability of worsening was 18% (95% CI: 14%-25%) among nonproliferative diabetic retinopathy eyes and 31% (95% CI: 23%-42%) among proliferative diabetic retinopathy eyes (P = 0.01). In Years 1, 3, and 5, the mean (SD) number of ranibizumab injections was 8.1 (2.5), 2.2 (2.6), and 1.8 (2.6) for nonproliferative diabetic retinopathy eyes, and 9.0 (2.8), 2.3 (2.9), and 1.7 (2.6) for proliferative diabetic retinopathy eyes, respectively. Proportions with improvement or rates of worsening did not change with time. CONCLUSION: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti-vascular endothelial growth factor therapy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Bressler SB, Odia I, Glassman AR, et al. CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report. Retina. 2018. PMID: 30234859. doi:10.1097/IAE.0000000000002302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。